Acasti Pharma, Inc. - Common Stock (ACST)

Competitors to Acasti Pharma, Inc. - Common Stock (ACST)

Amarin Corporation plc 

Amarin Corporation focuses on the development and commercialization of therapeutics to improve cardiovascular health, particularly with its drug Vascepa, which has a similar target market to Acasti's pharmaceutical offerings, such as CaPre. Both companies are centered on omega-3 fatty acids for treating high triglyceride levels, and they compete in clinical outcomes, regulatory approvals, and market penetration within the lipid management category.

Centaura Health

Centaura Health offers various health services that emphasize holistic and preventive healthcare strategies, incorporating diet and nutrition services which overlap into the domains that Acasti is targeting through pharmaceutical means. They are not direct competitors as they do not focus on pharmaceutical products, but their positioning in educating on triglyceride management creates an indirect competition for consumer attention and market focus. Acasti has a clear technological and product-driven advantage in the prescription sector.

Ocean Bio-Chem, Inc.

Ocean Bio-Chem is involved in producing and marketing products that are similar in composition to Acasti's offerings, though they focus more on consumer health products rather than pharmaceutical solutions. Their competition arises from being in adjacent markets that utilize omega-3 fatty acids, albeit with a different emphasis. Acasti, with its focus on prescription drugs, competes for recognition and credibility as a pharmaceutical developer, while Ocean Bio-Chem targets the consumer health space.

Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on developing innovative drug therapies for cancer and central nervous system disorders. While their primary focus overlaps with cancer drugs, they often participate in collaborations and partnerships that could intertwine with cardiovascular therapies. This competitive dynamic exists in the realm of biopharmaceutical technologies, though Acasti specifically targets cardiovascular disorders, which grants them a niche advantage over Rexahn.